نتایج جستجو برای: avastin bevacizumab

تعداد نتایج: 11361  

Journal: :journal of current ophthalmology 0
محمد ریاضی اصفهانی mohammad riazi-esfahani رضا کارخانه reza karkhaneh رامک روحی پور ramak roohipour مرتضی مواسات morteza movasat

purpose: to study the effects of adding intravitreal bevacizumab (avastin) to conventional laser treatment on regression of retinal neovascularization in threshold rop. methods: intravitreal injection of bevacizumab (1.25 mg) in one eye of each of three newborns with threshold rop was performed in addition to laser treatment. the other eye of each patient was treated with laser alone. changes i...

Journal: :Oncology 2009
Alberto Sobrero Stephen Ackland Stephen Clarke Ramón Perez-Carrión Silvana Chiara John Gapski Paul Mainwaring Bernd Langer Scott Young

BACKGROUND Bevacizumab (Avastin) significantly improves overall survival (OS) and progression-free survival (PFS) when combined with first-line irinotecan (IFL) plus bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic colorectal cancer (CRC). This open-label, phase IV trial evaluated the efficacy and safety of first-line bevacizumab in combination with IFL and infusional...

2013
Yong Liu Minoru Suzuki Shin-ichiro Masunaga Yi-Wei Chen Genro Kashino Hiroki Tanaka Yoshinori Sakurai Mitsunori Kirihata Koji ONO

Previous studies have demonstrated that angiogenesis inhibitors can enhance tumor inhibitory effects of chemo- and radiotherapy via their action on tumor vessels. Here, we studied the effect of the angiogenesis inhibitor, bevacizumab (Avastin), on boron distribution in a murine tumor model. The human head and neck squamous cell carcinoma cell line was used for inoculation into mice. Boron-10 co...

2014
Niko Kivinen Michaela Dithmer Kati Kinnunen Ralph Lucius Johann Roider Kai Kaarniranta Alexa Klettner

The most common reason for blindness in developed countries is age-related macular degeneration (AMD) that can be classified into two main categories: the atrophic, or dry form and the exudative, or wet form. The diagnostic difference between dry and wet AMD is the development of choroidal neovascularization in wet AMD. A master regulator in the development of neovascularization is Vascular End...

Journal: :The oncologist 2008
Wilfred D Stein James Yang Susan E Bates Tito Fojo

BACKGROUND To hasten cancer drug development, new paradigms are needed to assess therapeutic efficacy. In a randomized phase II study in patients with renal cell carcinoma, 10 microg/kg bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) administered every 2 weeks resulted in a longer time to progression but a statistically significant difference in overall survival could not be dem...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2011
N C Tebbutt F Murphy D Zannino K Wilson M M Cummins E Abdi A H Strickland R M Lowenthal G Marx C Karapetis J Shannon D Goldstein S S Nayagam R Blum L Chantrill R J Simes T J Price

BACKGROUND Bevacizumab is an antiangiogenic mAb with efficacy against several cancers, but it is associated with risk of arterial thromboembolism (ATE). Further data are needed to determine the safety of bevacizumab. PATIENTS AND METHODS We recorded grade 3, 4, or 5 ATE events and other data (including age, baseline cardiovascular risk factors, history of ATE, and aspirin use) from 471 patien...

Journal: :Retina 2009
Tom S Chang Gregg Kokame Raynor Casey Jonathan Prenner Leonard Feiner Nick Anderson

PURPOSE To compare the effectiveness of three consecutive intravitreal injections of bevacizumab (Avastin) and ranibizumab (Lucentis) in patients with treatment-naïve neovascular age-related macular degeneration. METHODS This is a retrospective comparative study of qualifying consecutively treated patients (n = 176) with new-onset subfoveal choroidal neovascularization presenting at 6 retina ...

Journal: :Neuro-oncology 2016
Frank Saran Olivier L Chinot Roger Henriksson Warren Mason Wolfgang Wick Timothy Cloughesy Sunita Dhar Emanuela Pozzi Josep Garcia Ryo Nishikawa

BACKGROUND The proposed use of bevacizumab with radiotherapy/temozolomide for newly diagnosed glioblastoma raised potential safety concerns. Bevacizumab has been linked with stroke, bleeding events, and wound-healing complications in other tumor types; these events are of particular concern for glioblastoma (highly vascular tumors that are usually resected). Published data on the interaction of...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید